For the Inventor, By the Inventor

Enter assignee name

Seattle, WA, United States of America

Omeros Corporation

USPTO Granted Patents = 99

% Expired Patents = 11.1

CIPO Patents = 17

EPO Patents = 45

Trademarks = 17

Forward Citations = 807

Loading Chart...

Loading Chart...

113 inventors (with patents filed for the assignee):

Gregory A Demopulos (47 out of 65 patents)

Thomas Dudler (23 out of 24 patents)

Neil S Cutshall (23 out of 24 patents)

4. Jennifer Lynn Gage (20 out of 36 patents)

5. Hans-Wilhelm Schwaeble (16 out of 19 patents)

6. Jeffrey M Herz (15 out of 27 patents)

7. Munehisa Yabuki (12 out of 15 patents)

8. Clark E Tedford (12 out of 18 patents)

9. Thomas L Little, Jr (12 out of 29 patents)

10. Larry W Tjoelker (11 out of 25 patents)

11. W Jason Cummings (10 out of 13 patents)

12. Wayne Richard Gombotz (9 out of 20 patents)

13. Christi L Wood (9 out of 9 patents)

14. James Brian Parent (9 out of 14 patents)

15. Peter Kurt Nollert Von Specht (9 out of 10 patents)

Core Competencies:

MASP-2 Inhibitors

Therapeutic Antibodies

Complement Activation

Graft-Versus-Host Disease

PDE10 Inhibitors

Fibrosis Treatment

Ocular Inflammation

Addiction Treatment

Chimeric Inhibitors

Monoclonal Antibodies

Optically Active Compounds

Bioactive Peptides

99 patents: Sort by Forward Citations

1. 12703684 - MASP-2 INHIBITORS AND METHODS OF USE (2026-08-11),

2. 12692229 - MASP-2 INHIBITORS AND METHODS OF USE (2026-07-28),

3. 12351648 - Methods of inhibiting MASP-2 for the treatment and/or prevention of coronavirus-induced acute respiratory distress syndrome (2025-07-08),

4. 12195427 - MASP-2 inhibitors and methods of use (2025-01-14),

5. 12129290 - Monoclonal antibodies, compositions and methods for detecting complement factor D (2024-10-29),

6. 12110288 - MASP-2 inhibitors and methods of use (2024-10-08),

7. 12091468 - Therapeutic antibodies that bind to the serine protease domain of MASP-2 and uses thereof (2024-09-17),

8. 12030853 - MASP-2 inhibitors and methods of use (2024-07-09),

9. 12005117 - Methods for inhibiting fibrosis in a subject in need thereof (2024-06-11),

10. 11981749 - Methods for treating conditions associated with MASP-2 dependent complement activation (2024-05-14),

11. 11981748 - Methods for inhibiting angiogenesis in a subject in need thereof (2024-05-14),

12. 11945848 - Chimeric inhibitor molecules of complement activation (2024-04-02),

13. 11896621 - Methods for treating and/or preventing graft-versus-host disease and/or diffuse alveolar hemorrhage and/or veno-occlusive disease associated with hematopoietic stem cell transplant (2024-02-13),

14. 11884742 - Methods for treating conditions associated with MASP-2 dependent complement activation (2024-01-30),

15. 11883493 - Antibodies specifically binding to MASP-3 for the treatment of various diseases and disorders (2024-01-30),

Company Overview

Omeros Corporation, based in Seattle, WA, specializes in the development of innovative therapeutics focused on complement activation inhibition. The company is at the forefront of research in areas such as MASP-2 inhibitors and therapeutic antibodies, targeting conditions like graft-versus-host disease, ocular inflammation, and fibrosis. Omeros is also exploring treatments for addiction and other complex diseases, leveraging its expertise in complement biology to address unmet medical needs.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

99 Patents

#22 in Seattle, WA

#67 in Washington

#3,827 in US

#7,853 in the World

Seattle, WA, United States of America

Omeros Corporation

Forward Citations = 807

113 inventors:

Gregory A Demopulos (47 out of 65 patents)

Thomas Dudler (23 out of 24 patents)

Neil S Cutshall (23 out of 24 patents)

4. Jennifer Lynn Gage (20 out of 36 patents)

5. Hans-Wilhelm Schwaeble (16 out of 19 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Omeros Corporation. Retrieved from https://idiyas.com/company/omeros

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…